# Docetaxel-Induced Pneumonitis in a Patient With Metastatic Lung Adenocarcinoma

## TL;DR

A patient with lung cancer developed pneumonitis after docetaxel treatment and improved with steroids.

## Contribution

This case highlights docetaxel-induced pneumonitis as a rare but important side effect in lung cancer treatment.

## Key findings

- The patient showed a favorable response to docetaxel but developed pneumonitis.
- High-dose steroids were effective in treating the pneumonitis after infections were ruled out.

## Abstract

Docetaxel is a taxane anti-neoplastic agent commonly used in the treatment of solid-organ tumours. Here, we describe a case of a patient with metastatic lung adenocarcinoma who had disease progression following initial treatment with a combination of pembrolizumab, pemetrexed and carboplatin. She received three cycles of docetaxel and had a favourable oncological response but was admitted for breathlessness following the third cycle. A repeat computed tomography scan of the thorax showed predominantly right-sided ground-glass opacities and consolidation. The patient underwent high-risk bronchoscopy and bronchoalveolar lavage. Once infection was confidently ruled out, she was started on high-dose steroid therapy and responded to treatment.